Skip to main content

Table 1 Results of IGF parameters

From: Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes

Parameter

Unit

Insulin aspart (a)

BIAsp70 (b)

BIAsp50 (c)

Human insulin (d)

p

Total IGF-I

      

Baseline

μg/l

113 (109–117)

121 (116–125)

117 (113–121)

115 (111–120)

NS

Cmax

μg/l

124 (121–126)

124 (122–126)

122 (120–125)

122 (119–124)

NS

Cmin

μg/l

113 (111–114)

113 (111–115)

112 (110–114)

113 (111–115)

NS

AUC0-3 h

μg*h/l

353 (349–357)

355 (351–359)

353 (349–357)

353 (350–357)

NS

AUC3-6 h

μg*h/l

349 (337–362)

370 (358–383)

356 (344–369)

352 (340–365)

NS

AUC6-9 h

μg*h/l

346 (333–361)

364 (352–378)

351 (339–364)

349 (336–362)

NS

AUC0-9 h

μg*h/l

1071 (1053–1090)

1071 (1055–1088)

1059 (1043–1074)

1064 (1048–1081)

NS

Bioactive IGF

      

Baseline

μg/l

0.60 (0.54-0.67)

0.62 (0.56-0.69)

0.68 (0.61-0.76)

0.58 (0.52-0.65)

NS

Cmax

μg/l

0.80 (0.76-0.84)

0.79 (0.75-0.83)

0.79 (0.75-0.84)

0.82 (0.78-0.87)

NS

Cmin

μg/l

0.46 (0.43-0.50)

0.50 (0.47-0.54)

0.52 (0.49-0.56)

0.52 (0.48-0.56)

NS

AUC0-3 h

μg*h/l

2.02 (1.96-2.09)

1.96 (1.90-2.02)

2.04 (1.98-2.11)

2.08 (2.02-2.15)

.051

AUC3-6 h

μg*h/l

2.16 (2.02-2.31)

2.11 (1.98-2.25)

2.26 (2.11-2.41)

2.27 (2.13-2.43)

NS

AUC6-9 h

μg*h/l

1.82 (1.68-1.98)

1.90 (1.76-2.05)

1.99 (1.85-2.15)

1.98 (1.83-2.14)

NS

AUC0-9 h

μg*h/l

6.11 (5.80-6.45)

5.98 (5.71-6.27)

6.18 (5.89-6.49)

6.43 (6.12-6.75)

NS

IGFBP-1

      

Baseline

μg/l

130 (107–159)

140 (115–171)

116 (95–141)

144 (118–176)

NS

Cmin

μg/l

14 (11–18)c

21 (16–27)

26 (20–34)a

22 (17–29)

.009

Tmin

min

259 (234–284)

256 (231–280)

231 (206–255)

268 (244–293)

NS

AUC0-3 h

μg*h/l

262 (233–294)c

319 (284–359)

351 (312–396)a,d

256 (228–288)c

.001

AUC3-6 h

μg*h/l

112 (81–155)

132 (96–183)

164 (119–227)d

83 (60–114)c

.029

AUC6-9 h

μg*h/l

662 (496–884)

577 (445–747)

455 (351–589)

390 (298–510)

NS

AUC0-9 h

μg*h/l

1092 (906–1317)

1084 (917–1282)d

1032 (871–1224)

779 (654–927)b

.025

IGFBP-2

      

Baseline

μg/l

342 (312–375)

356 (324–390)

356 (325–391)

380 (347–417)

NS

Cmax 0-6 h

μg/l

477 (459–497)

473 (455–493)

462 (444–480)

465 (447–485)

NS

Tmax 0-6 h

min

215 (185–245)

215 (185–245)

218 (188–248)

205 (175–235)

NS

AUC0-3 h

μg*h/l

1225 (1191–1261)

1224 (1189–1259)

1184 (1151–1219)

1212 (1177–1247)

NS

AUC3-6 h

μg*h/l

1278 (1170–1395)

1303 (1194–1423)

1263 (1157–1378)

1363 (1249–1488)

NS

AUC6-9 h

μg*h/l

1127 (1015–1251)

1261 (1149–1385)

1221 (1112–1340)

1247 (1132–1374)

NS

AUC0-9 h

μg*h/l

3717 (3548–3892)

3758 (3609–3916)

3640 (3495–3792)

3651 (3498–3813)

NS

IGFBP-3

      

Baseline

mg/l

3.04 (2.97-3.11)

3.12 (3.05-3.19)

3.05 (2.97-3.12)

3.01 (2.94-3.08)

NS

Cmax

mg/l

3.30 (3.23-3.37)

3.32 (3.25-3.39)

3.30 (3.24-3.37)

3.25 (3.18-3.32)

NS

Cmin

mg/l

2.98 (2.94-3.02)

3.00 (2.96-3.04)

2.98 (2.94-3.02)

2.99 (2.95-3.03)

NS

AUC0-3 h

mg*h/l

9.23 (9.12-9.34)

9.22 (9.11-9.33)

9.23 (9.12-9.34)

9.20 (9.09-9.31)

NS

AUC3-6 h

mg*h/l

9.40 (9.16-9.66)

9.67 (9.42-9.93)

9.44 (9.19-9.69)

9.26 (9.02-9.51)

NS

AUC6-9 h

mg*h/l

9.45 (9.19-9.72)

9.87 (9.63-10.12)

9.60 (9.36-9.84)

9.46 (9.22-9.71)

NS

AUC0-9 h

mg*h/l

28.19 (27.71-28.68)

28.50 (28.05-28.94)

28.33 (27.90-28.77)

28.16 (27.71-28.61)

NS

  1. The results for Cmax, Cmin, Tmax, Tmin and AUCs are expressed as geometric mean (range) drawn from ANOVA. The outcomes were controlled for baseline levels (t = 0) if necessary, ap < 0.05 vs insulin aspart, bp < 0.05 vs BIAsp70, cp < 0.05 vs BIAsp50, dp < 0.05 vs human insulin.